2022
- Divergent trajectories of antiviral memory after SARS-CoV-2 infection. Nat Commun. 2022 Mar 10;13(1):1251. doi: 10.1038/s41467-022-28898-1. PubMed PMID: 35273178; PubMed Central PMCID: PMC8913789.
- COMBAT consortium. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell. 2022 Mar 3;185(5):916-938.e58. doi: 10.1016/j.cell.2022.01.012. Epub 2022 Jan 21. PubMed PMID: 35216673; PubMed Central PMCID: PMC8776501.
- Constructing custom-made radiotranscriptomic signatures of vascular inflammation from routine CT angiograms: a prospective outcomes validation study in COVID-19. Lancet Digit Health. 2022 Oct;4(10):e705-e716. doi: 10.1016/S2589-7500(22)00132-7. Epub 2022 Aug 26.
- MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination. Cell Mol Immunol. 2022 Feb;19(2):234-244. doi: 10.1038/s41423-021-00814-5. Epub 2022 Jan 7.
2021
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1.
- Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021 Jun;27(6):1113. doi: 10.1038/s41591-021-01372-z. PubMed PMID: 33958800; PubMed Central PMCID: PMC8101331.
- Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021 Jun;27(6):1116. doi: 10.1038/s41591-021-01363-0. PubMed PMID: 34021278.
- Systems Immunology: Revealing Influenza Immunological Imprint. Viruses. 2021 May 20;13(5). doi: 10.3390/v13050948. Review. PubMed PMID: 34065617; PubMed Central PMCID: PMC8160800.
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021 Mar 6;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3. Epub 2021 Feb 19. PubMed PMID: 33617777; PubMed Central PMCID: PMC7894131.
- Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021 Feb;27(2):279-288. doi: 10.1038/s41591-020-01179-4. Epub 2020 Dec 17. PubMed PMID: 33335322.
- T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021 Feb;27(2):270-278. doi: 10.1038/s41591-020-01194-5. Epub 2020 Dec 17. PubMed PMID: 33335323.
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1.
- SIMON: Open-Source Knowledge Discovery Platform. Patterns (N Y). 2021 Jan 8;2(1):100178. doi: 10.1016/j.patter.2020.100178. eCollection 2021 Jan 8. PubMed PMID: 33511368; PubMed Central PMCID: PMC7815964.
2020
- Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine. Mol Syst Biol. 2020 Nov;16(11):e9888. doi: 10.15252/msb.20209888. PubMed PMID: 33210468; PubMed Central PMCID: PMC7674973.
2019
- The FluPRINT dataset, a multidimensional analysis of the influenza vaccine imprint on the immune system. Sci Data. 2019 Oct 21;6(1):214. doi: 10.1038/s41597-019-0213-4. PubMed PMID: 31636302; PubMed Central PMCID: PMC6803714.
- SIMON, an Automated Machine Learning System, Reveals Immune Signatures of Influenza Vaccine Responses. J Immunol. 2019 Aug 1;203(3):749-759. doi: 10.4049/jimmunol.1900033. Epub 2019 Jun 14. PubMed PMID: 31201239; PubMed Central PMCID: PMC6643048.
2018
- Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells. Nat Immunol. 2018 May;19(5):453-463. doi: 10.1038/s41590-018-0082-6. Epub 2018 Apr 9. PubMed PMID: 29632329.
2016
- Activation of Innate and Adaptive Immunity by a Recombinant Human Cytomegalovirus Strain Expressing an NKG2D Ligand. PLoS Pathog. 2016 Dec;12(12):e1006015. doi: 10.1371/journal.ppat.1006015. eCollection 2016 Dec. PubMed PMID: 27907183; PubMed Central PMCID: PMC5131914.
- Inflammatory monocytes and NK cells play a crucial role in DNAM-1-dependent control of cytomegalovirus infection. J Exp Med. 2016 Aug 22;213(9):1835-50. doi: 10.1084/jem.20151899. Epub 2016 Aug 8. PubMed PMID: 27503073; PubMed Central PMCID: PMC4995080.
2014
- Cytomegalovirus m154 hinders CD48 cell-surface expression and promotes viral escape from host natural killer cell control. PLoS Pathog. 2014 Mar;10(3):e1004000. doi: 10.1371/journal.ppat.1004000. eCollection 2014 Mar. PubMed PMID: 24626474; PubMed Central PMCID: PMC3953435.
2013
- Superior induction and maintenance of protective CD8 T cells in mice infected with mouse cytomegalovirus vector expressing RAE-1γ. Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16550-5. doi: 10.1073/pnas.1310215110. Epub 2013 Sep 19. PubMed PMID: 24052528; PubMed Central PMCID: PMC3799388.